Krystal Biotech Inc
KRYS
View Detailed Chart
285.970USD
+3.700+1.31%
Close 02/02, 16:00（ET）Quotes delayed by 15 min
8.29BMarket Cap
41.46P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+1.31%
5 Days
+2.59%
1 Month
+15.82%
6 Months
+82.17%
Year to Date
+15.99%
1 Year
+79.02%
View Detailed Chart
TradingKey Stock Score of Krystal Biotech Inc
Currency: USD Updated: 2026-02-02Key Insights
Krystal Biotech Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 3 out of 393 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 290.82.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Krystal Biotech Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Krystal Biotech Inc Highlights
StrengthsRisks
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.
Fairly Valued
The company’s latest PE is 40.92, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 28.79M shares, decreasing 5.05% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 444.77K shares of this stock.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
290.818
Target Price
+4.15%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Krystal Biotech Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Krystal Biotech Inc Info
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.
Ticker SymbolKRYS
CompanyKrystal Biotech Inc
CEOKrishnan (Krish S)
Websitehttps://www.krystalbio.com/
Related Instruments
+0.20%
+0.27%
+0.25%
+0.37%
-2.00%
-0.33%
+0.34%
-0.20%
-0.29%
-2.78%
-0.76%
+0.34%
-0.91%
+0.61%
+0.88%
-1.70%
0.00%
0.00%
-0.11%
-0.38%Popular Symbols
268.350
-1.660 (-0.61%)
186.980
+1.370 (+0.74%)
78204.670
+236.030 (+0.30%)
278.000
+7.770 (+2.88%)
2304.460
-14.700 (-0.63%)
426.620
+4.810 (+1.14%)
4926.180
+274.460 (+5.90%)
62.306
+0.306 (+0.49%)
1.180
+0.001 (+0.06%)
155.848
+0.265 (+0.17%)
